Article Details
Retrieved on: 2024-11-07 21:02:45
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses Maravai LifeSciences' acquisition of Officinae Bio's DNA and RNA business to enhance mRNA manufacturing capabilities using AI in TriLink BioTechnologies. This move strengthens their position in biotechnology, particularly RNA therapeutics and synthetic biology.
Article found on: www.stocktitan.net
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here